Company Overview
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -14.59% |
| 6 Months: | -44.73% |
| 3 Months: | -57.83% |
| 1 Month: | -41.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 94.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CALC CalciMedica, Inc. PHARMA | 2.02 | -0.29 | $13.79M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -10.37M | -7.80M | -6.04M | -6.82M | -11.49M | -7.74M | -8.02M | -4.21M | -3.59M | -3.29M | -22.34M | -6.58M | -4.83M | -5.77M | -6.53M | -5.74M | -6.50M | -6.62M | -5.62M | -5.61M |
| Net Income | -6.29M | -10.26M | -10.21M | -7.79M | -5.87M | -4.72M | -11.45M | -7.71M | -7.99M | -3.63M | -3.03M | -2.58M | -19.29M | -6.30M | -4.62M | 130.00K | -3.95M | -5.62M | -5.04M | -5.96M | -7.80M | 4.98M |
| Diluted EPS | - | - | - | - | - | - | - | -0.36 | -0.38 | -46.13 | -36.55 | -31.04 | -23.43 | -1.11 | -0.82 | 0.01 | -0.36 | -0.50 | -0.36 | -0.40 | -0.52 | 0.30 |
| R&D Expense | - | - | 8.40M | 6.08M | 4.63M | 4.76M | 6.45M | 4.17M | 4.02M | 2.92M | 2.26M | 1.24M | 6.49M | 3.81M | 2.77M | 2.94M | 4.16M | 3.55M | 4.22M | 4.05M | 3.85M | 3.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -37.50M | -29.83M | -35.95M | -14.19M | -38.08M | -24.20M | -23.12M |
| Net Income | -37.04M | -27.53M | -35.82M | -7.82M | -34.36M | -13.70M | -29.56M |
| Diluted EPS | - | - | -1.69 | -111.16 | -7.66 | -1.22 | -1.97 |
| R&D Expense | 30.58M | 20.96M | 18.90M | 8.35M | 15.86M | 14.48M | 15.23M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 40.66M | 101.79M | 69.09M | 3.35M | 12.19M | 19.79M | 13.59M |
| Total Equity | -66.79M | -102.95M | 94.79M | -63.99M | -71.30M | 8.16M | 14.41M | -6.64M |
| Cash & Equivalents | - | 15.87M | 33.42M | 13.36M | 1.33M | 5.53M | 7.93M | 11.52M |
| Total Liabilities | - | 12.25M | 7.01M | 4.07M | 12.58M | 4.03M | 5.38M | 20.23M |
| Current Liabilities | - | 12.25M | 7.00M | 4.06M | 4.78M | 4.03M | 3.68M | 3.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.21M | -32.06M | -31.50M | -11.76M | -25.73M | -21.15M | -21.18M |
| Investing Cash Flow | -20.62M | -42.56M | 10.75M | -4.00K | 8.88M | -4.42M | 9.55M |
| Financing Cash Flow | 54.87M | 92.17M | 695.00K | 8.48M | 20.90M | 27.97M | 15.21M |
| Capital Expenditure | -605.00K | -1.02M | -488.00K | -4.00K | -78.00K | -8.00K | -28.00K |
| Free Cash Flow | -31.82M | -33.09M | -31.99M | -11.76M | -25.81M | -21.15M | -21.21M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 36.0% | -29.0% | 56.0% | 11.0% | -421.2% | -95.1% | 445.1% |
| ROCE % | -132.0% | -31.5% | -55.3% | 991.8% | -466.8% | -150.2% | -235.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Woodline Partners LP | 7.29% | 497.95K | $956.06K |
| 2 | Heights Capital Management, Inc | 4.56% | 311.22K | $597.53K |
| 3 | Squadron Capital Management LLC | 3.65% | 248.97K | $478.03K |
| 4 | Stempoint Capital LP | 3.65% | 248.97K | $478.03K |
| 5 | Stonepine Capital Management, LLC | 1.82% | 124.49K | $239.01K |
| 6 | L1 Global Manager Pty Ltd | 0.73% | 49.79K | $95.60K |
| 7 | Morgan Stanley | 0.42% | 28.65K | $55.01K |
| 8 | Geode Capital Management, LLC | 0.32% | 22.09K | $42.42K |
| 9 | Renaissance Technologies, LLC | 0.28% | 19.46K | $37.36K |
| 10 | Vanguard Capital Management LLC | 0.26% | 17.79K | $34.16K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CALC
Investors can meet CalciMedica on Sept. 15 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOcVQ4R1FWeUtLb1VBMWhubDJQYnpLY0FLV0RCTGlXOGlXVHZnSjA0S1J4YjVXWldRWFlxZC1aU1lzZWF5TW9lR2J1VUxfRERaUXBFTUg5Q0VOQ0tfX0tDcjdmUXlXeDJEUFZHdXV1X0w1TmJnaWkxWlhfZUZtbFM2UVFJd3lSQmVXRHRWej…
CalciMedica, Inc. (CALC) Stock Price & News - Syfe
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE56MUNhTnVNNUtacENoSm5LcW5oNGZPQjBOUExRbk05ajJSdzhEN0ZrbFo2WWZtVU91UjhJeFQxZWhyMkRpYVBPclVrUQ?oc=5" target="_blank">CalciMedica, Inc. (CALC) Stock Price & News</a> <font …
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program - PR Newswire
<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxNX1RXRDRhTFBEZktrbjFBd3lDcjZocG0zQXVjSU10M0hTbzFlRVBXSmhNTUFPcHh6NlpzOC1sV21xS1VBTVhST01EWHhELTVtX2JGcmdIeXhXOHZfTllqWjhGOHhHRm90YmtJRGJmX2JNd3ZVNnVmc2REamNERDZuR3B0ZzZVY0RVMnBicD…
Market Movers | Winners: AEMD, HYFM, FUSE | Losers: GYGY, CALC, MIRA - Trefis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxONmpZejhMN1plVjVocTU4ZFo2M1c3ajlfbkppWmszcmdQSTZrUG9qS1A0MS1peFlVeVVfZ2RZZXBzSUNjVDUwZ3l2SUtMRjREOEp3THZTRllyV29NMmExZjY0c2h3X09xb2tfNUxDTEtaNjVwVFJBaUJHQ200aldZcENNR21feEhTQmExQ2…
CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQUV9JQWdWUTVNa1NpSTVpOXFYTTZjdFR1VXF0em12ZHJuQWlJcXNoSnNEeUlYVGdnU1dQNzk3YkxuVUVRZXdNSEZNUTdfdzl0MlNxNllWRU5FTEt2YndfSl9pWlRraHRKQjdrV0tTZW9xSm9UV3IwbzRQR29fRHQ1ZTdubXNOalI4dUNMMi…
CALC Stock Slumped 76% On Wednesday — Here’s Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNTE9mX1c4U1NjWWhXVHY2WjdPUXc3aTFJWFJHUVZDS2tucFQ4aWphMHJqWmlwWmVUTjNQTVB2QmdnX0R5bnVXdU1tSHNLa24xQmRCN041QTdOUl83UnlSMTBwREJoREUwYjJvdFVRa0ZPeFZLVFEwLU04NFFraGZwY2NDX2tuU3BVZzJpTE…
CALC — Frequently Asked Questions
What is the current share price of CalciMedica, Inc. (CALC)?
As of 2026-09-19 21:16 PDT, CalciMedica, Inc. (CALC) trades at $2.02 on NasdaqCM. Its 52-week range is $2.00 to $33.70.
What is the market capitalisation of CALC?
CalciMedica, Inc. (CALC) has a market capitalisation of $13.79M on NasdaqCM.
What is the P/E ratio of CALC?
CALC trades at a trailing price-to-earnings (P/E) ratio of -0.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.56.
Is CALC a good stock to buy?
This page provides a data-driven analysis of CalciMedica, Inc. (CALC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.